PRESS RELEASE published on 11/28/2023 at 12:40, 2 years 3 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
PRESS RELEASE published on 11/15/2023 at 12:45, 2 years 4 months ago NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
PRESS RELEASE published on 11/14/2023 at 12:45, 2 years 4 months ago Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
PRESS RELEASE published on 10/16/2023 at 12:45, 2 years 5 months ago NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial is Highly Active Against Coronaviruses as well as RSV
PRESS RELEASE published on 10/12/2023 at 12:45, 2 years 5 months ago NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
PRESS RELEASE published on 08/21/2023 at 12:45, 2 years 7 months ago The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
PRESS RELEASE published on 07/11/2023 at 12:45, 2 years 8 months ago Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
PRESS RELEASE published on 07/06/2023 at 12:45, 2 years 8 months ago Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
PRESS RELEASE published on 06/29/2023 at 12:45, 2 years 8 months ago NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
PRESS RELEASE published on 05/31/2023 at 12:40, 2 years 9 months ago NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
Published on 03/26/2026 at 04:55, 2 hours 36 minutes ago Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives
Published on 03/26/2026 at 00:40, 6 hours 51 minutes ago Challenger RC Resource Upgrade Drilling Complete
Published on 03/26/2026 at 00:30, 7 hours 1 minute ago Nano One Highlights Recent Objectives & Reports Fourth Quarter 2025 Results
Published on 03/25/2026 at 19:15, 12 hours 16 minutes ago Gemina Laboratories Ltd. Announces Delisting from the CSE
Published on 03/25/2026 at 13:30, 18 hours 1 minute ago Prince Silver Files NI 43-101 Technical Report for Its Stampede Gap Porphyry Copper-Gold-Molybdenum Project in Nevada
Published on 03/26/2026 at 07:27, 4 minutes ago Delivery Hero reports adj EBITDA up 30% in 2025, as Quick Commerce and key markets gain momentum
Published on 03/26/2026 at 07:11, 19 minutes ago Berentzen-Gruppe Aktiengesellschaft publishes its 2025 Annual Report – Berentzen Group achieves significant consolidated profit
Published on 03/26/2026 at 07:07, 23 minutes ago Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026
Published on 03/26/2026 at 07:05, 25 minutes ago Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children
Published on 03/26/2026 at 07:05, 26 minutes ago EDAG Group: Market uncertainty and delayed awarding of projects shape FY 2025 – Strategic measures accelerated to restore sustainable growth and competitiveness
Published on 03/25/2026 at 18:53, 12 hours 37 minutes ago CIS - Transfert Contrat de Liquidité Portzamparc - 25.03.2026
Published on 03/25/2026 at 18:31, 13 hours ago Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 18:31, 13 hours ago Performance soutenue des Investissements et déploiement actif de la stratégie
